Success Metrics

Clinical Success Rate
82.2%

Based on 37 completed trials

Completion Rate
82%(37/45)
Active Trials
6(10%)
Results Posted
65%(24 trials)
Terminated
8(13%)

Phase Distribution

Ph phase_3
10
16%
Ph phase_2
14
22%
Ph not_applicable
5
8%
Ph phase_4
20
32%
Ph early_phase_1
2
3%
Ph phase_1
7
11%

Phase Distribution

9

Early Stage

14

Mid Stage

30

Late Stage

Phase Distribution58 total trials
Early Phase 1First-in-human
2(3.4%)
Phase 1Safety & dosage
7(12.1%)
Phase 2Efficacy & side effects
14(24.1%)
Phase 3Large-scale testing
10(17.2%)
Phase 4Post-market surveillance
20(34.5%)
N/ANon-phased studies
5(8.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.8%

37 of 53 finished

Non-Completion Rate

30.2%

16 ended early

Currently Active

6

trials recruiting

Total Trials

63

all time

Status Distribution
Active(6)
Completed(37)
Terminated(16)
Other(4)

Detailed Status

Completed37
Withdrawn8
Terminated8
Recruiting5
unknown3
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
63
Active
6
Success Rate
82.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.4%)
Phase 17 (12.1%)
Phase 214 (24.1%)
Phase 310 (17.2%)
Phase 420 (34.5%)
N/A5 (8.6%)

Trials by Status

withdrawn813%
terminated813%
unknown35%
suspended12%
active_not_recruiting12%
completed3759%
recruiting58%

Recent Activity

Clinical Trials (63)

Showing 20 of 63 trialsScroll for more
NCT05450718Phase 4

Low-dose Buprenorphine Initiation for Opioid Use Disorder

Recruiting
NCT03968237

Measures to Improve Outcomes After an Opioid Overdose

Withdrawn
NCT05011266Phase 2

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

Recruiting
NCT01841931Phase 4

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients

Terminated
NCT03616236Phase 3

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

Suspended
NCT04771689Phase 4

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

Withdrawn
NCT04091009Phase 4

Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms

Withdrawn
NCT05944952Phase 4

Low-dose Versus a High-dose Sublingual Buprenorphine Induction

Active Not Recruiting
NCT04893525Phase 2

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

Recruiting
NCT04447287Phase 1

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Completed
NCT04818086Phase 1

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

Completed
NCT05062577Phase 2

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Withdrawn
NCT03908437Phase 4

Rapid Initiation of Drug Treatment Engagement

Completed
NCT05644587Phase 4

Novel Induction to Buprenorphine/Naloxone

Terminated
NCT04480554Phase 2

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

Recruiting
NCT04234191Phase 2

Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Recruiting
NCT04794790Early Phase 1

Buprenorphine Induction for Fentanyl Dependent Opioid Users

Withdrawn
NCT03976258

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

Completed
NCT01843751Phase 3

Dane County Drug Court Study for Addicted Offenders

Completed
NCT03026790Phase 2

Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study

Completed

Drug Details

Intervention Type
DRUG
Total Trials
63